Oncology Biosimilars Market Report by Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032
The global oncology biosimilars market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.3 Billion by 2032, exhibiting a growth rate (CAGR) of 22.3% during 2024-2032.
Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.
Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.
Breakup by Drug Type:
Monoclonal Antibody
Immunomodulators
G-CSF
Hematopoietic Agents
Others
Breakup by Cancer Type:
Lung Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Kidney Cancer
Stomach Cancer
Brain Cancer
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others
Breakup by Region:
Europe
Asia Pacific
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.
Key Questions Answered in This Report:
How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oncology biosimilars industry?
What are the key regional markets in the global oncology biosimilars industry?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the cancer type?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global oncology biosimilars industry?
What are the key driving factors and challenges in the global oncology biosimilars industry?
What is the structure of the global oncology biosimilars industry and who are the key players?
What is the degree of competition in the global oncology biosimilars industry?
Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.
Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.
Breakup by Drug Type:
Monoclonal Antibody
Immunomodulators
G-CSF
Hematopoietic Agents
Others
Breakup by Cancer Type:
Lung Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Kidney Cancer
Stomach Cancer
Brain Cancer
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others
Breakup by Region:
Europe
Asia Pacific
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.
Key Questions Answered in This Report:
How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oncology biosimilars industry?
What are the key regional markets in the global oncology biosimilars industry?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the cancer type?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global oncology biosimilars industry?
What are the key driving factors and challenges in the global oncology biosimilars industry?
What is the structure of the global oncology biosimilars industry and who are the key players?
What is the degree of competition in the global oncology biosimilars industry?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BIOSIMILARS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Type
5.5 Market Breakup by Cancer Type
5.6 Market Breakup by Distribution Channel
5.7 Market Breakup by Region
5.8 Market Forecast
6 MARKET BREAKUP BY DRUG TYPE
6.1 Monoclonal Antibody
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Immunomodulators
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 G-CSF
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Hematopoietic Agents
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 MARKET BREAKUP BY CANCER TYPE
7.1 Lung Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Colorectal Cancer
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cervical Cancer
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Breast Cancer
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Kidney Cancer
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Stomach Cancer
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Brain Cancer
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast
8 MARKET BREAKUP BY DISTRIBUTION CHANNEL
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Online Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Retail Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 Europe
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Asia Pacific
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 North America
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Middle East and Africa
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Latin America
9.5.1 Market Trends
9.5.2 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Biocon Limited
14.3.2 Celltrion Inc.
14.3.3 Dr. Reddy's Laboratories Ltd.
14.3.4 Intas Pharmaceuticals Ltd.
14.3.5 STADA Arzneimittel AG
14.3.6 Pfizer Inc.
14.3.7 Apotex Inc.
14.3.8 Teva Pharmaceutical Industries Ltd.
14.3.9 Sandoz International GmbH
14.3.10 BIOCAD Biotechnology Company
14.3.11 Mylan N.V.
14.3.12 F. Hoffmann-La Roche AG
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BIOSIMILARS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Type
5.5 Market Breakup by Cancer Type
5.6 Market Breakup by Distribution Channel
5.7 Market Breakup by Region
5.8 Market Forecast
6 MARKET BREAKUP BY DRUG TYPE
6.1 Monoclonal Antibody
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Immunomodulators
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 G-CSF
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Hematopoietic Agents
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 MARKET BREAKUP BY CANCER TYPE
7.1 Lung Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Colorectal Cancer
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cervical Cancer
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Breast Cancer
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Kidney Cancer
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Stomach Cancer
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Brain Cancer
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast
8 MARKET BREAKUP BY DISTRIBUTION CHANNEL
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Online Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Retail Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 Europe
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Asia Pacific
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 North America
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Middle East and Africa
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Latin America
9.5.1 Market Trends
9.5.2 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Biocon Limited
14.3.2 Celltrion Inc.
14.3.3 Dr. Reddy's Laboratories Ltd.
14.3.4 Intas Pharmaceuticals Ltd.
14.3.5 STADA Arzneimittel AG
14.3.6 Pfizer Inc.
14.3.7 Apotex Inc.
14.3.8 Teva Pharmaceutical Industries Ltd.
14.3.9 Sandoz International GmbH
14.3.10 BIOCAD Biotechnology Company
14.3.11 Mylan N.V.
14.3.12 F. Hoffmann-La Roche AG
LIST OF TABLES
Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Oncology Biosimilars Market Structure
Table 7: Global: Oncology Biosimilars Market: Key Players
Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Oncology Biosimilars Market Structure
Table 7: Global: Oncology Biosimilars Market: Key Players
LIST OF FIGURES
Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023
Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023
Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023
Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
Figure 10: Global: Oncology Biosimilars Industry: Porter’s Five Forces Analysis
Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023
Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023
Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023
Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
Figure 10: Global: Oncology Biosimilars Industry: Porter’s Five Forces Analysis
Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
